Even using statins, 1 in 5 with DM has hypertriglyceridemia

  • Fan W & al.
  • Diabetes Care
  • 01.10.2019

  • von Miriam Tucker
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Almost one-fifth of US adults with diabetes mellitus (DM) have residual hypertriglyceridemia (HTG) despite statin use, and they are at increased atherosclerotic cardiovascular disease (ASCVD) risk.

Why this matters

  • HTG is significantly associated with future ASCVD risk.

Study design

  • Study of 1448 US adults aged ≥20 years with diabetes in 2007-2014 National Health and Nutrition Examination Survey, comparing prevalence of borderline HTG (TG 150-199 mg/dL) and HTG (≥200 mg/dL) by statin use and low-density lipoprotein cholesterol (LDL-C) levels.
  • Funding: Amarin Pharma, Inc.

Key results

  • Prevalences: borderline HTG, 20.1% (projected to 4.9 million population); HTG, 22.5% (5.5 million).
  • HTG was found in 19.5% of statin users and 25.3% of nonstatin users.
  • In those with LDL-C
  • Prevalences of 10-year estimated ASCVD risks ≥7.5% were:
    • 68.7% with normal TG, 
    • 62.7% with borderline HTG, and
    • 77.5% with HTG.
  • One-third with HTG overall and ~40% of statin users had ASCVD risk ≥20%.

Limitations

  • Cross-sectional.
  • Results limited to population studied.
  • No information regarding duration, intensity, and adherence of statin use.